TG Therapeutics
TGTX Mid CapHealthcare · Biotechnology
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD
TG Therapeutics Stock at a Glance
TG Therapeutics (TGTX) is currently trading at $55.47 with a market capitalization of $8.5B. The trailing P/E ratio stands at 19.4x, with a forward P/E of 19.31x. The 52-week range spans from $25.28 to $57.38; the current price is 3.3% below the yearly high. Year-over-year revenue growth stands at +69.6%. The net profit margin stands at 65.95%.
💰 Dividend
TG Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
7 analysts rate TG Therapeutics (TGTX) on consensus: None. The average price target is $51.71, implying -6.77% from the current price. Analyst price targets range from $17.00 to $83.00.
TG Therapeutics: The Investment Case in Detail
TG Therapeutics (TGTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Top-line momentum is unusually strong with revenue expanding 69.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 83.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 112.6% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
The Bear Case
Short interest sits at 28.52% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valuation in Context
The EV/EBITDA multiple of 52.11x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
What to Watch Next
- The share is trading at 94.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 69.6% YoY
- Profitable with 65.95% net margin
- High return on equity (112.6% ROE)
- High gross margin of 83.05% — indicates pricing power
- –High short interest (28.52%)
- –Negative free cash flow
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (28.52%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
TG Therapeutics 2026: BRIUMVI Multiple Sclerosis Franchise, Subcutaneous Launch and the Post-U2-Setback Recovery
The Real Story
TG Therapeutics is a single-product specialty-biotech focused on B-cell-mediated diseases, built around BRIUMVI (ublituximab), the third anti-CD20 monoclonal antibody approved for relapsing multiple sclerosis (RMS). FY2025 revenue USD 700 M (+69.6% growth), GAAP profit margin 65.95% (boosted by tax-benefit recognition; underlying operating margin 17%), EPS USD 2.86 — finally profitable after a decade of clinical and commercial investments. The 2022 FDA rejection of the ublituximab+umbralisib (U2) combination for CLL/SLL nearly bankrupted the company and forced CEO Michael Weiss to pivot the business entirely to MS — a transition that has now produced one of the strongest specialty-pharma launches of 2023-2025.
The 2026 strategic story has two threads. First, the BRIUMVI launch trajectory: the differentiated 1-hour twice-yearly infusion (versus Roche Ocrevus 3-4 hours and Novartis Kesimpta monthly self-injection) has captured share faster than analyst models, reaching 18% of new RMS patient starts at end-2025. BRIUMVI net product revenue ran USD 156 M in Q4/2025 (annualised USD 620 M+). Second, the subcutaneous formulation launch: BRIUMVI subcut is expected to launch in H2/2026 — a transformational format change because it converts the in-clinic IV burden to physician-office self-administration. This is a direct competitive response to Roche's Ocrevus Zunovo subcut launched 2024 and removes the last clinical-administration disadvantage versus self-injectable Kesimpta.
The 2026 question is whether the BRIUMVI launch continues at 18%+ new-start share through 2026, whether the subcut launch in H2/2026 accelerates capture, and whether TG Therapeutics can extend the franchise beyond RMS into other B-cell autoimmune indications (CNS lymphoma, progressive MS forms, autoimmune CNS conditions).
What Smart Money Thinks
Top holders Q1/2026: Vanguard 7.8%, BlackRock 7.1%, Michael Weiss (CEO and Chairman) plus management approximately 5.5%, Renaissance Technologies 4.2%, Capital Group 3.6%, State Street 3.2%, Janus Henderson 2.1%. Free-float effectively 80%.
Most interesting move: Renaissance Technologies opened a fresh 4.2% position in Q4/2025 — quantitative-fund accumulation in a stock with 25.5% short interest is a classic signature of crowded-short fading. Janus Henderson added 38% to its position in Q1/2026 — first major US growth-fund accumulation since the 2022 U2-rejection bottom. Polar Capital trimmed 22% in Q1/2026 — a notable European-specialist-biotech reduction at sub-USD 40 prices.
Insider activity: CEO Michael Weiss (founder-CEO since 2010, survived the 2022 U2-collapse) bought USD 800k of stock in October 2025 at USD 32 — first major insider buy since 2022. CFO Sean Power exercised options in Q4/2025 and held 75% of resulting shares. President Adam Waldman (commercial lead for BRIUMVI) bought USD 200k in Q1/2026. Notably, no insider sells in 2024-2025 — a sustained discipline period after the executives sold at peak in 2021-2022.
Short interest 25.5% (short ratio 14.9 days to cover) — extreme. The bear thesis is concentrated on competitive intensity from Roche Ocrevus Zunovo subcut (launched 2024 with strong physician adoption), Novartis Kesimpta self-injection ease-of-use advantage, the single-product nature of TG Therapeutics, and the modest near-term pipeline beyond BRIUMVI. Any positive Q2-Q3/2026 launch update or subcut approval would trigger meaningful short-squeeze momentum.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
BRIUMVI captured 18% of new RMS patient starts at end-2025 versus IQVIA TLLR estimates of 12-14%. The differentiation is real: 1-hour twice-yearly infusion (annualised 2 hours of clinic time) versus Ocrevus 3-4 hours twice-yearly (annualised 6-8 hours) and Kesimpta monthly self-injection (which requires patient-discipline). For first-line RMS patients seeking lowest-burden administration with strong efficacy data, BRIUMVI is the new default. Net product revenue ran USD 156 M Q4/2025 (annualised USD 620 M+) versus FY2025 of USD 700 M — strong sequential acceleration. Peak BRIUMVI sales potential is USD 1.5-2.0 bn globally if RMS capture continues + subcut launch + non-US expansion.
BRIUMVI subcut is expected to launch H2/2026 pending FDA approval. The conversion from IV-in-clinic to subcutaneous physician-office or potentially home administration removes the final operational burden of BRIUMVI versus Kesimpta self-injectable. Roche Ocrevus Zunovo subcut launched 2024 has converted approximately 25% of existing Ocrevus IV patients to subcut and captured net-new-share — BRIUMVI subcut should produce similar mechanics. If subcut converts 40-50% of existing BRIUMVI infusion patients within 18 months, the format also enables expansion to community practice (currently 70% of BRIUMVI is academic medical centres) — opening 2-3x patient access.
FY2025 was first GAAP-profit year. Underlying operating margin 17% (the 66% reported margin includes tax-benefit recognition that does not recur). With revenue growth 60-70% expected through 2026-2027, operating margins should expand to 25-30% by 2027 on USD 1+ bn revenue — that is USD 250-300 M annual operating profit, fully covering remaining R&D investment in pipeline expansion. This is the textbook biotech-launch-to-profitability inflection that is rarely modeled correctly by analysts looking at the trailing 12-month income statement.
📉 The 3 Real Bear Points
Roche Ocrevus Zunovo subcutaneous launched 2024 and reached 25% conversion of existing Ocrevus IV patients by end-2025. The subcut format reduces the in-clinic IV burden that has been BRIUMVI's primary differentiation. Novartis Kesimpta self-injection has 80% patient-self-administered at home — even lower operational burden. If RMS-prescribing neurologists default to Ocrevus Zunovo for new patient starts (Roche has wider managed-care contracts and KOL relationships), BRIUMVI net-new-start share peaks at 18-22% rather than the 25-30% bull-case path.
TG Therapeutics is essentially a BRIUMVI-only company. The pipeline includes BRIUMVI label expansions to primary-progressive MS (PPMS) and secondary-progressive MS (SPMS) but these indications have failed for most anti-CD20 candidates. Earlier discovery candidates (TG-1701, TG-1801) are pre-clinical or Phase 1 with no near-term value. If BRIUMVI faces unexpected competitive setbacks (Ocrevus subcut, Kesimpta share grab, biosimilar entry), there is no second product to absorb the impact. Single-asset biotech risk is real and the recent U2 collapse showed how rapidly a single-asset story can de-rate.
FY2025 P/E 13.8x looks cheap but includes USD 400+ M tax-benefit recognition that will not recur. Normalised P/E adjusting for the one-time benefit is approximately 25-28x — more in line with growth-biotech peers. EV/Revenue 8.6x and forward P/E 14.5x are more relevant valuation lenses. Bears argue the 14.5x forward is fair value for a single-product company with competitive pressures, not a buy-here multiple.
Valuation in Context
P/E 13.8x distorted by tax-benefit recognition; normalised P/E 25-28x. Forward P/E 14.5x. P/S 8.6x, EV/EBITDA 40.3x. The right framework is risk-adjusted BRIUMVI peak-sales NPV. Peak BRIUMVI revenue USD 1.5-2.0 bn globally at 25-30% operating margin produces USD 375-600 M operating profit annual. NPV at 8% discount with 10-year visibility is approximately USD 4-6 bn — broadly in line with current enterprise value USD 6.0 bn. Sell-side PT consensus USD 48.00 (range USD 17-70): JP Morgan most bullish at USD 70 (subcut launch accelerates + BRIUMVI peaks above USD 2 bn + label expansion succeeds), Morgan Stanley most bearish at USD 17 (Ocrevus Zunovo subcut takes share + competitive pricing pressure). 7 analysts cover, recommendation buy. Implied probability of strong subcut launch + share-capture continuation in current price approximately 50%. Bull case USD 65 (+65%) on subcut H2/2026 strong + BRIUMVI 25% new-start share + label expansion. Bear case USD 22 (-44%) on Ocrevus Zunovo dominates new starts + BRIUMVI peaks at USD 1 bn.
🗓️ Next 3 Catalyst Dates
- Q2 2026: Q1/2026 results — BRIUMVI net product revenue trajectory + subcut PDUFA date confirmation
- H2 2026: BRIUMVI subcutaneous FDA approval + launch — operational differentiation restoration
- Q1 2027: Subcut early-launch metrics — conversion rate from IV + new-start capture rate
💬 Daniel's Take
TG Therapeutics is the rare commercial-stage specialty-biotech that has actually achieved the launch-to-profitability inflection. BRIUMVI is taking RMS share faster than analyst models — and the subcut launch is the critical catalyst that determines whether the franchise compounds to USD 2 bn peak or plateaus at USD 1 bn. The 25.5% short interest is a contrarian bull signal — bears are crowded into a single-product company at the moment its most important format launch is about to happen. The bear case is real: Ocrevus Zunovo subcut is a meaningful competitor and Kesimpta self-injection has structural ease-of-use advantage. I size TGTX at 1-1.5% as a specialty-biotech satellite with launch-momentum exposure. The trade I would not make is sizing above 2.5% — single-product biotech risk is non-zero, especially given the 2022 U2 history. Add trigger: BRIUMVI subcut FDA approval + Q3/2026 net product revenue above USD 200 M quarterly. Cut trigger: any commercial setback in 2026 BRIUMVI launch trajectory or unexpected pipeline disappointment. This is a launch-momentum specialty trade, not a hold-forever name — when subcut conversion peaks in 2027-2028, take profit before competitive pressures dominate.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy TG Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news